Design of liposomal nanocarriers with a potential for combined dexamethasone and bevacizumab delivery to the eye

[Display omitted] Clinicians face numerous challenges when delivering medications to the eyes topically because of physiological barriers, that can inhibit the complete dose from getting to the intended location. Due to their small size, the ability to deliver drugs of different polarities simultane...

Full description

Saved in:
Bibliographic Details
Published in:International journal of pharmaceutics 2024-04, Vol.654, p.123958-123958, Article 123958
Main Authors: Farooq, Umer, O'Reilly, Niall J., Ahmed, Zubair, Gasco, Paolo, Raghu Raj Singh, Thakur, Behl, Gautam, Fitzhenry, Laurence, McLoughlin, Peter
Format: Article
Language:English
Subjects:
Bevacizumab
Dexamethasone
Drug Delivery Systems
Eye
Liposomes
Particle Size
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[Display omitted] Clinicians face numerous challenges when delivering medications to the eyes topically because of physiological barriers, that can inhibit the complete dose from getting to the intended location. Due to their small size, the ability to deliver drugs of different polarities simultaneously, and their biocompatibility, liposomes hold great promise for ocular drug delivery. This study aimed to develop and characterise a dual loaded liposome formulation encapsulating Bevacizumab (BEV) and Dexamethasone (DEX) that possessed the physicochemical attributes suitable for topical ocular delivery. Liposomes were prepared by using thin film hydration followed by extrusion, and the formulations were optimised using a design of experiments approach. Physicochemical characterisation along with cytocompatibility and bioactivity of the formulations were assessed. Liposomes were successfully prepared with a particle size of 139 ± 2 nm, PDI 0.03 ± 0.01 and zeta potential −2 ± 0.7 mV for the optimised formulation. BEV and DEX were successfully encapsulated into the liposomes with an encapsulation efficiency of 97 ± 0.5 % and 26 ± 0.5 %, respectively. A sustained release of BEV was observed from the liposomes and the bioactivity of the formulation was confirmed using a wound healing assay. In summary, a potential topical eye drop drug delivery system, which can co-load DEX and BEV was developed and characterised for its potential to be used in ocular drug delivery.
ISSN:0378-5173
1873-3476
DOI:10.1016/j.ijpharm.2024.123958